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Identity 
Other names: 18A2; 42A; CAPL; FSP1; MTS1; 
P9KA; PEL98 
HGNC (Hugo): S100A4 
Location: 1q21.3 
Local order: The 1q21 locus harbours the epidermal 
differentiation complex (EDC) encompassing a 2.05 
Mbp of human genomic DNA. The S100 family genes 
except the S100beta are arranged in the following 
order: 1 cen-S100A10-S100A11-THH (trychohyalin)-
FLG (profilaggrin)-IVL (involucrin)-LOR (loricrin)-
S100A9-S100A12-S100A8-S100A7-S100A6-S100A5-
S100A4-S100A3-S100A2-S100A13-S100A1-1qtel. 
S100beta is located on 21q22.3 (Schäfer et al., 1995; 
Marenholz et al., 1996; Mischke et al., 1996). 
DNA/RNA 
Note 
Starts 153516089 bp from pter; ends 153522612 bp 
from pter; 6524 bases; orientation minus strand. 
Homo sapiens chromosome 1, GRCh37 primary 
reference assembly. 
NCBI reference sequence: NC_000001.10, 
NT_004487.19. 
 
Figure 1. A. Chromosome 1 ideogram showing the location of S100A4 based on National Library of Medicine Handbook. B. The position 
of S100A4 is based on Entrez Gene ID 6275 (not drawn to scale). 
 






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10)   878 
 
Figure 2. Not drawn to scale. 
 
 
Figure 3. Sequence. 
 
Description 
The human S100A4 gene has four exons. Exon 1 is 
non-coding and exons 2 and 3 are coding exons. Exon 
2 with the start codon and encodes N-terminal EF hand 
and exon 3 encodes the C-terminal EF-hand. The fourth 
non-coding exon occurs in the 5'-UTR. 
Transcription 
Two variant RNA transcripts from Source Search. The
NM_019554 is a longer transcript. NM_002961 
possesses alternate 5'-UTR; both encode the same 
protein isoform. 
NCBI reference sequence NM_019554 ver 01954.2 
564 bp mRNA; NM 002961 ver 002961.2; 512 bp 
mRNA. 
Splice variants have been reported of only S100A4 
among the S100 family. Alternative splicing within the 
5'-untranslated region (UTR) generates the two 
variants. Both variants, hu-mts1 and hu-mts1 (var), 
contain one open reading frame, differ slightly in 
translational capacity; possess similar stability. A splice 
transcript with loss of non-coding exon 1a/1b, but 
exons 2 and 3 present has been described in infiltrating 
carcinoma of the breast. Splice variant with exons 1, 3, 
and 4 and another with exons 2 and 3, may be 
differentially expressed in non-malignant and 
malignant tissues. One would note nonetheless that 
Alternative Splicing and Transcript Diversity (ASTD) 
have listed 12 variant transcripts. 
Regulation of transcription 
Binding sites for several transcription factors have been 
identified in the promoter of S100A4. SABiosciences 
ChIP-qPCR Assay database lists 19 p53 binding sites. 
Multiple NFAT (nuclear factor of activated T cells) 
transcription factor consensus binding sites; NF-
kappaB related binding site (Tulchinsky et al., 1997). 
Much evidence is also available regarding activation of 
NF-kappaB by S100A4.  
S100A4 has been postulated to signal via RAGE 
(receptor for advanced glycation end products) which is 
known to activate NF-kappaB. 
A composite enhancer consisting of 6 cis-elements has 
been identified in the first intron of murine S100A4. 
This interacts with Sp1 and AP-1 family members and
CBF (core binding factor alpha) and KRC (zinc finger 






Human S100A4 (also mouse and rat S100A4) contains 
101 aminoacid residues and is approx 12 kDa in size. 
In common with most S100 family members, S100A4 
is an antiparallel homodimer stabilised by noncovalent 
interactions between two helices from each subunit 
forming an X-type four-helix bundle. Each subunit has 
two calcium-binding EF-hands linked by the 
intermediate hinge region and a distinctive C-terminal 
extension. A pseudo-EF hand formed by helices 1 and 
2 and the pseudo-EF-hand and a canonical EF-hand 
that are brought into proximity by a small two-stranded 
antiparallel beta-sheet. The hinge region and the C-
terminal loop of S100 proteins are involved in target 
protein binding. Calcium binding produces a 
conformational change, which leads to the exposure of 
hydrophobic pocket of residues in helices 3 and 5, the 
hinge region and the C-terminal loop. This 
conformational change is required for target protein 
binding. S100A4 might be post-translationally 
modified.NCBI sequence: NM_002961; NP_002952; 
NM_019554; NP_062427; UniProtKB/Swiss-Prot: 
P26447. 
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Figure 4. S100A4 undergoes a calcium-dependent conformational rearrangement that exposes the protein target binding cleft. Ribbon 
diagrams showing the NMR solution structure of apo-S100A4 (PDB code 1M31) and the X-ray structure of calcium-bound S100A4 (PDB 
code 2Q91). Following the addition of calcium (yellow spheres), helix 3 (green helix in dark blue monomer) moves to expose the target 
bind cleft. This conformational rearrangement is required for S100A4 binding to protein targets. The author is grateful to Anne R. 





EF hand 1: length 36; position 12-47, 
EF hand 2: length 36; position 50-84. 
Target protein interaction domains: in the active state 
S100A4 interacts with many target proteins e.g. p53
family proteins, HDM2, Annexin II, F-actin, 
tropomyosin, and the heavy chain of non-muscle 
myosin IIA, among others. These target proteins 
interact with specific binding domains of S100A4, 
which are accessible upon conformational change of 
the apoprotein upon Ca2+ binding. 
Expression 
S100A4 is distributed ubiquitously in normal tissue 
(Mazzucchelli, 2002). 
For expression profile: Human Protein Atlas (HPA): 
CAB002618 and Human Protein Reference Database 
HPRD. 
S100A4 occurs in many forms of human cancer, e.g. 
breast, colorectal, liver, lung, head and neck, ovarian, 
endometrial, pancreatic, renal, testicular, and prostate 
cancers, and melanoma; also in many cell lines of 
myeloid, lymphoid, lung and brain origin and cell lines 
derived from many forms of leukaemias. S100A4 has 
been implicated in other human diseases, e.g. Crohn's 
disease and rheumatoid arthritis. 
Localisation 
S100A4 occurs extracellulary and also in cytoplasmic 
and nuclear location. Differential distribution has been 
reported between stromal components of primary and 
metastatic tumour. Patterns of distribution could vary 
between tissues as well between species. No firm 
functional link has been made with the site/s of 
localisation. Expression patterns need to be explored in 
more than one tumour system. This might be crucial in 
the development of strategies of treatment targetin 
S100A4, especially with the postulated link of S100A4 
expression with chemoresistance. 
Function 
S100A4 protein promotes metastasis, functions as a 
counter point to metastasis suppressor nm23, and is 
implicated in the regulation of the cell cycle, cell 
proliferation, motility, invasion, tubulin polymerisation, 
and angiogenesis. 
S100A4 promotes metastatic spread of cancer as 
demonstrated by gene transfer studies. Its expression 
has shown clear correlation with tumour spread to 
lymph nodes and with prognosis. 
Cell cycle, cell proliferation, tumour growth and 
apoptosis. S100A4 binds to and forms complexes with 
p53 to regulate cell cycle progression. P53 has been 
confirmed as target of S100A4, which stabilises p53. 
S100A4 binds to C-terminal regulatory region of p53. 
S100A4 and certain other members of the S100 family 
bind to TAD transactivation domain (residues 1-57) of 
p53. They may also affect p53 function by binding to 
the tetramerization domain of p53 (residues 325-355) 
and interfering with intracellular translocation and 
subcellular localisation. This interaction is suggested to 
be linked with p53 function. Nineteen p53 binding site  
have been identified in the promoter of S100A4 
(SABiosciences ChIP-qPCR Assay). S100A4 also 
influences p21waf1 and mdm2, a regulator of p53 
function and the apoptosis family bax gene. It binds to 
N-terminal domain of mdm2. Signalling pathways 
include P53-Rb/stathmin/p53 down stream effectors, 
e.g. p21waf, p16 etc. P53/stathmin signalling modulates 
microtubule dynamics and cell division. Furthermore, 
p53 and down stream target apoptosis family genes 
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such as BNIP3, caspases; calpain/Fas (?) are postulated 
as important pathways in S100A4 signalling. 
Knockdown of S100A4 has been reported to lead to 
apoptosis. The transcription factor NF-kappaB which 
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S100A4 proliferative signalling seems to involve 
epidermal growth factor receptors (EGFR). EGFR 
expression correlates with S100A4 expression. 
Interactive signalling with HER2 might be postulated 
with the finding that S100A4 stimulates EGFR/HER2 
receptor signalling and on the identification in human 
S100A4 promoter of an HER2 response element 1099-
1487 bp up stream of the transcription start site. The 
interaction of S100A4 with the TGF-beta system via 
Smad has also been reported. S100A4 seems able to 
bind to the N-ter region of Smad3. TGF-beta is an 
important activator of epithelial mesenchymal 
transition leading to acquisition of invasive ability. The 
interaction between S100A4 and Smad thus falls in 
place with the metastasis-promoting function of the
former. Some of these pathways are pictorially 
represented above (figure 5). 
Invasion, motility, and intercellular adhesion. 
Signalling systems include modulation of cytoskeletal 
dynamics; cadherin/catenin complex cytoskeletal 
linkage and significantly a TCF, a component of the
canonical Wnt signalling system, binding site has been 
identified in the S100A4 promoter and S100A4 directly 
binds heterodimeric beta-catenin/TCF complexes; 
CD44/cytoskeletal linkage; ECM associated proteolytic 
enzyme system/ECM remodelling, affects tubulin 
polymerisation. S100A4 and tumour suppressor nm23 
exert opposite effects on tubulin dynamics. Two C-
terminal lysine residues are required for enhanced 
motility and invasion and interaction with target 
proteins. The connective tissue growth factor (CTGF) 
has been reported to up regulate S100A4 expression 
and inhibition of S100A4 blocks CTGF-induced cell 
motility. 
Angiogenesis signalling occurs via activation of 
MMP/TIMP; activation of angiogenic factors 
VEGF/endothelial cell proliferation; MetAP2/p53-
mediated inhibition of endothelial cell proliferation. 
S100A4 stimulates angiogenic signalling in breast 
cancer. An indirect link is suggested by the inhibition 
of S100A4 by Interferon-gamma which might inhibit 
angiogenesis by down regulating VEGF expression. 
Shown below are the potential pathways of S100A4 
signalling in cell motility/invasion and angiogenesis, 
emphasising the possibility that S100A4 seems able to 
influence many significant systems leading to 
angiogenesis. 
Homology 
Sequence homology to protein from Pan troglodytes 
(Chimpanzee) (Gene ID: 457320; Protein NCBI 
RefSeq: XP_001138744.1). 
Bos taurus (Bovine) (Gene ID: 282343). 
Canis lupus familiaris (Gene ID: 403787; NCBI 
reference sequence: NP_001003161.1; protein: 
NP_777020.1). 
Sequence homology 93% to murine S100A4 (Entrez 
Gene ID 20198; NP_035441). 
Sequence homology 91% to rat protein (Entrez Gene 
ID 24615; NP_036750). 
Mutations 
Note 
Many SNPs have been identified; 7 shown in NCBI 
and 26 in Applied Biosystems data source. The NCBI 
Entrez SNP database lists 19 submissions. 
Chromosomal rearrangements 
The locus 1q21 is a hotspot for chromosomal 
rearrangements, microdeletions and duplications; 
significance uncertain and there are no clear 
implications for metastasis. No translocations leading 
to hybrid S100A4 have been recorded. 
There are 11 common and 1 rare fragile sites on 
chromosome 1. The common FRA1F occurs in 1q21. 
Chromosome 1 is prone to sister chromatid 
recombination (SCR) and >70% SCRs occur at the 
fragile sites or in the same band as the fragile sites, but 




No simple mutations, gene fusions, or structural 
variants detected in breast and colorectal carcinomas 
and in gliomas (Cosmic: Catalogue Of Somatic 
Mutations In Cancer, Welcome Trust Sanger Institute). 
No mutations have been found coding regions in 
human, canine and feline S100A4. Mutating 
phenylalanine 72 to alanine reduces functional 
effectiveness. Toombak dipping (placing between the 
lower lip and gums) has been linked with S100A4 
mutations in oral squamous cell carcinoma, but 
mutations have been described also in non-dippers. The 
carcinoma from dippers had 4 mutations (one 
transition, 3 transversions) and non-snuff-dippers 
showed 3 mutations each (one transition, 2 
transversions). 
Implicated in 
General notes on association with 
human cancer 
Note 
S100A4 has been implicated in the progression and 
prognosis of several forms of human cancer, e.g. breast, 
colorectal, gastric, pancreatic and bladder cancer, 
SCLC and oesophageal squamous cell carcinoma, 
among others. Poor prognosis associated with high 
S100A4 expression is accompanied by clear signs of 
disease progression, e.g. high histological and clinical 
grades and involvement of lymph nodes. 
Also indicative of poor prognosis is high S100A4 
expression coupled with reduced E-cadherin expression 
in pancreatic, oral squamous cell carcinoma and in  
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melanoma. S100A4 expression is inversely related with
expression of metastasis suppressor nm23 and with 
prognosis of breast cancer. 
Cytogenetics 
No cytogenetic data are available. 
Abnormal protein 




Both tumour and serum levels are reportedly enhanced 
in breast cancer patients. S100A4 expression is 
inversely related to that of the metastasis suppresso  
nm23 in breast cancers. Tumour levels might correlate 
with proliferative state and shown to be linked with p53 
dysfunction. S100A4 proliferative signalling seems to 
involve epidermal growth factor receptors (EGFR). 
Breast cancers that are high S100A4s expressers tend to 
be oestrogen (ER)/progesterone receptor (PR) negativ . 
Given that ER/PR expression is inversely related to the 
expression of epidermal growth factor receptors, 
ER/PR status together with S100A4/nm23 expression 
status seem to be able to provide significant leads to the 
prediction of prognosis. S100A4 signalling could 
interact with HER2 function; this is suggested by the 
finding that S100A4 stimulates EGFR/HER2. Up 
regulated expression was associated with increased 
tumour angiogenesis and this would be expected to 
contribute to the invasive ability of breast cancer. 
Prognosis 




Primary cancers show enhanced S100A4 expression 
and associated with metastatic disease in the lymph 
nodes. Up regulation of its expression has been 
correlated with enhanced invasion, nodal 
dissemination. Nuclear expression has been reported to 
be a prognostic indicator. As in the case of breast 
cancer there are indications that S100A4 might interact 




Higher expression S100A4 has been observed and this 
might be associated with muscle invasion. 
Prognosis 
High expression has been related to decreased survival. 
Ovarian cancer 
Note 
The expression of nuclear S100A4 expression is 
associated with more aggressive disease in primary 
carcinoma where the level of expression has been 
reported to be higher in solid tumours than in effusions. 
Lung cancer 
Note 
Higher expression of S100A4 has been encountered in 
squamous cell but not adenocarcinoma of the lung. 
Prognosis 
A large study of the expression levels has revealed 
significantly predictive of survival in squamous cell but 
not adenocarcinoma of the lung. S100A4 was 
significantly associated with patients' poor prognosis in 




S100A4 up regulation might be accompanied by 
reduced E-cadherin expression. This inverse 
relationship has also been encountered in melanoma 
and oral squamous cell carcinoma cell lines. This might 
generate an additive effect on tumour aggression. 
Prognosis 
Some preliminary evidence is available indicating that 
S100A4 expression levels relate to shorter overall 
survival of patients with pancreatic cancer. 
Gastric cancer 
Note 
Higher expression of S100A4 has been noted in gastric 
cancer and correlated with the presence of the tumour 
in lymph node and the occurrence of distant metastase , 
and with poor prognosis. Consistent with the situaton 
in certain other forms of cancer, in gastric cancer 
S100A4 levels inversely relate to E-cadherin 
expression. Indeed, down regulation of E-cadherin has 




A marked inverse relationship has been described 
between S100A4 and E-cadherin in these tumours. 
Crohn's disease (a form of irritable 
bowel disease) 
Note 
S100A4 expression is increased in structure fibroblasts 




Increase S100A4 mRNA found in proliferating 
synovial fibroblasts. Also protein expression up 
regulated in rheumatoid arthritis synovial linked with 
joint invasion. IL-7 and S100A4 occurs in cartilage 
osteoarthritis and can lead to increased MMP-13 
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production by chondrocytes. The JAK/STAT/RAGE 
signalling has been implicated here. 
Psoriasis 
Note 
Many S100 proteins are found in the dermis. S100A4 is 
up regulated in the dermis and colossal release of the 
protein has been reported. Enhanced stabilisation of 
p53 near cells expressing S100A4 has been noticed. It 
appears to affect cell proliferation and induce 
angiogenesis. 
Cardio-vascular, nervous and 
pulmonary systems 
Note 
S100A4 may be involved in disorders of these system, 
but data currently available are somewhat fragmentary. 
Both S100A4 mRNA and protein are said to be up 
regulated in the hypertrophic hearts. Up regulation 
occurs is associated with hypertrophy induced by aortic 
stenosis or myocardial infarction. In vitro, recombinant 
S100A4 protein increases the density viable cardiac 
myocytes. The ERK1/ERK2 signalling system has been 
found to be activated in these processes. 
Breakpoints 
Note 
A 1q21 breakpoint was described some time ago in 
renal cell carcinoma (RCC)-associated (X;1)(p11;q21) 
translocation. This has been mapped to the S100 gene
cluster, but its link with S100A4 is uncertain. No 
translocations involving S100A4 have been recorded. 
No fusion proteins or hybrid genes involving S100A4 
are known. 
There are 11 common and 1 rare fragile sites on 
chromosome 1. The common FRA1F occurs in 1q21. 
Chromosome 1 is prone to sister chromatid 
recombination (SCR) and >70% SCRs occur at the 
fragile sites or in the same band as the fragile sites, but 
no link with S100A4 has been established. 
 
 
To be noted 
Note 
S100A4 expression has been linked with 
chemoresistance, but the mechanisms involved remain 
to be elucidated. Whether this occurs via engagement 
of RAGE by S100A4 and activation of RAGE 
signalling leading up to chemoresistance is an avenue 
yet to be explored. 
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